MVM Partners LLP and Orbimed Advisors LLC investment in Proverum Limited

Friday, 29 August 2025

Byrne Wallace Shields LLP advised MVM Partners LLP, and Orbimed Advisors LLC, in connection with the Series B equity investment in Proverum Limited, a Dublin-based company focused on the development of novel minimally invasive technologies to treat BPH. The ProVee System uses a nitinol stent designed to gently re-shape the enlarged BPH prostate and alleviate the associated lower urinary tract symptoms. It is deployed through a low profile, flexible, steerable delivery system with integrated imaging, which is the same size as the office-based endoscopes routinely used for diagnosing BPH. Proceeds from the financing will be used to prepare for commercialization.

Byrne Wallace Shields LLP's team was led by partner Catherine Dowling (Partner, Corporate & Life Sciences) and Catherine Cusack (Senior Associate, Corporate & Life Sciences) and a multidisciplinary team across the firm.

The deal won the Equity Capital Markets: Financing Round category in the Finance Dublin Deals of the Year 2026.